CCHT(SZ:000661) Ge Long Hui A P P·2025-09-05 10:21Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd.'s subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received the acceptance notice for the clinical trial application of GenSci140 from the National Medical Products Administration, indicating progress in the development of a new targeted therapy for cancer patients [1][2]. Group 1 - GenSci140 is a novel dual-target antibody-drug conjugate that targets the folate receptor alpha (FRα), designed to enhance binding and internalization in tumor cells, thereby improving the delivery of the cytotoxic agent [1]. - The drug utilizes a cleavable linker and is loaded with a topoisomerase I (TOPOI) inhibitor, which directly kills tumor cells and enhances anti-tumor effects through a bystander killing effect [1][2]. Group 2 - Preclinical studies have demonstrated that GenSci140 exhibits strong tumor cell binding and internalization activity, showing significant anti-tumor effects across various models, including ovarian cancer, regardless of FRα expression levels [2]. - The innovative dual-target design and stable linker technology of GenSci140 suggest it may become a potential best treatment option for FRα-positive cancer patients, particularly those with low to medium FRα expression [2].